Sodium Channel Blockers in the Treatment of Epilepsy Martin J. Brodie Current Opinion 18 May 2017 Pages: 527 - 534
The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer’s Disease, Based on a Mechanistic Target of Rapamycin Pathway Lin Li Leading Article 24 May 2017 Pages: 535 - 549
Dopaminergic Therapies for Non-motor Symptoms in Parkinson’s Disease Eva SchaefferDaniela Berg Review Article 22 June 2017 Pages: 551 - 570
Ascorbic Acid to Manage Psychiatric Disorders Morgana MorettiDaiane Bittencourt FragaAna Lúcia S. Rodrigues Review Article 09 June 2017 Pages: 571 - 583
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs Peter Joseph Jongen Review Article Open access 12 June 2017 Pages: 585 - 602
Erratum to: Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs Peter Joseph Jongen Erratum 07 July 2017 Pages: 603 - 603
A Review of Adjunctive CNS Medications Used for the Treatment of Post-Surgical Pain Ajit RaiHoward MengHance Clarke Review Article 02 June 2017 Pages: 605 - 615
Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model Marjie L. HardRichard J. MillsLisa von Moltke Original Research Article Open access 08 June 2017 Pages: 617 - 624
Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe David R. CoghillTobias BanaschewskiAlessandro Zuddas Original Research Article Open access 30 June 2017 Pages: 625 - 638